This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44. doi: 10.1136/bjophthalmol-2016-309034CarvajalRDSchwartzGKTezelTMarrBFrancisJHNathanPDMetastatic disease from uveal melanoma: treatment options and future prospectsBr J Ophthalmol2017101384410.1136/bjophthalmol-2016-309034525612227574175Open DOISearch in Google Scholar
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-5. doi: 10.1016/j.ophtha.2011.01.040SinghADTurellMETophamAKUveal melanoma: trends in incidence, treatment, and survivalOphthalmology20111181881510.1016/j.ophtha.2011.01.04021704381Open DOISearch in Google Scholar
Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23: 8076-80. doi: 10.1200/JCO.2005.02.6534RietschelPPanageasKSHanlonCPatelAAbramsonDHChapmanPBVariates of survival in metastatic uveal melanomaJ Clin Oncol20052380768010.1200/JCO.2005.02.653416258106Open DOISearch in Google Scholar
Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol 2014; 25: 742-6. doi: 10.1093/annonc/mdt585LeyvrazSPiperno-NeumannSSuciuSBaurainJFZdzienickiMTestoriAet alHepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trialAnn Oncol201425742610.1093/annonc/mdt585443351724510314Open DOISearch in Google Scholar
Mariani P, Dureau S, Savignoni A, Rouic LL, Levy-Gabriel C, Piperno-Neumann S, et al. Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI. Cancers 2019; 11. doi: 10.3390/cancers11060863MarianiPDureauSSavignoniARouicLLLevy-GabrielCPiperno-NeumannSet alDevelopment of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRICancers20191110.3390/cancers11060863662781331234340Open DOISearch in Google Scholar
Lorenzo D, Piulats JM, Ochoa M, Arias L, Gutierrez C, Catala J, et al. Clinical predictors of survival in metastatic uveal melanoma. Jpn J Ophthalmol 2019; 63: 197-209. doi: 10.1007/s10384-019-00656-9LorenzoDPiulatsJMOchoaMAriasLGutierrezCCatalaJet alClinical predictors of survival in metastatic uveal melanomaJpn J Ophthalmol20196319720910.1007/s10384-019-00656-930796549Open DOISearch in Google Scholar
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99. doi: 10.1016/j.cell.2010.01.025GrivennikovSIGretenFRKarinMImmunity, inflammation, and cancerCell20101408839910.1016/j.cell.2010.01.025286662920303878Open DOISearch in Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013HanahanDWeinbergRAHallmarks of cancer: the next generationCell20111446467410.1016/j.cell.2011.02.01321376230Open DOISearch in Google Scholar
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome study. Br J Cancer 2011; 104: 726-34. doi: 10.1038/sj.bjc.6606087ProctorMJMorrisonDSTalwarDBalmerSMO’ReillyDSFoulisAKet alAn inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome studyBr J Cancer20111047263410.1038/sj.bjc.6606087304959121266974Open DOISearch in Google Scholar
Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, et al. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. Oncotarget 2018; 9: 6968-76. doi: 10.18632/oncotarget.24087JomrichGHollensteinMJohnMBaierlAPairederMKristoIet alThe modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junctionOncotarget2018969687610.18632/oncotarget.24087580552929467943Open DOISearch in Google Scholar
Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol 2019; 26: 31-47. doi: 10.1111/iju.13801OhnoYRole of systemic inflammatory response markers in urological malignancyInt J Urol201926314710.1111/iju.1380130253448Open DOISearch in Google Scholar
Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-9; discussion 390. doi: 10.1016/s0161-6420(91)32285-1GragoudasESEganKMSeddonJMGlynnRJWalshSMFinnSMet alSurvival of patients with metastases from uveal melanomaOphthalmology1991983839discussion 39010.1016/s0161-6420(91)32285-12023760Open DOISearch in Google Scholar
Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 2017; 11: 279-89. doi: 10.2147/OPTH.S89591KrantzBADaveNKomatsubaraKMMarrBPCarvajalRDUveal melanoma: epidemiology, etiology, and treatment of primary diseaseClin Ophthalmol2017112798910.2147/OPTH.S89591529881728203054Open DOISearch in Google Scholar
Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report No. 26. Arch Ophthalmol 2005; 123: 1639-43. doi: 10.1001/archopht.123.12.1639Diener-WestMReynoldsSMAgugliaroDJCaldwellRCummingKEarleJDet alDevelopment of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report No26. Arch Ophthalmol200512316394310.1001/archopht.123.12.163916344433Open DOISearch in Google Scholar
Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-9. doi: 10.1167/iovs.03-0538KujalaEMakitieTKivelaTVery long-term prognosis of patients with malignant uveal melanomaInvest Ophthalmol Vis Sci2003444651910.1167/iovs.03-053814578381Open DOISearch in Google Scholar
Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 2016; 21: 848-54. doi: 10.1634/theoncologist.2015-0522KukDShoushtariANBarkerCAPanageasKSMunhozRRMomtazPet alPrognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasisOncologist2016218485410.1634/theoncologist.2015-0522494339327286787Open DOISearch in Google Scholar
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol 2018; 10: 1758834018757175. doi: 10.1177/1758834018757175YangJMansonDKMarrBPCarvajalRDTreatment of uveal melanoma: where are we now?Ther Adv Med Oncol201810175883401875717510.1177/1758834018757175582491029497459Open DOISearch in Google Scholar
Bronkhorst IH, Jager MJ. Inflammation in uveal melanoma. Eye 2013; 27: 217-23. doi: 10.1038/eye.2012.253BronkhorstIHJagerMJInflammation in uveal melanomaEye2013272172310.1038/eye.2012.253357425323238448Open DOISearch in Google Scholar
Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45: 1950-8. doi: 10.1016/j.ejca.2009.01.023TeramukaiSKitanoTKishidaYKawaharaMKubotaKKomutaKet alPretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03Eur J Cancer2009451950810.1016/j.ejca.2009.01.02319231158Open DOISearch in Google Scholar
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20: 576-90. doi: 10.1016/j.ccr.2011.09.009LabelleMBegumSHynesRODirect signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasisCancer Cell2011205769010.1016/j.ccr.2011.09.009348710822094253Open DOISearch in Google Scholar
Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010; 16: 219-23. doi: 10.1038/nm.2084HoughtonAMRzymkiewiczDMJiHGregoryADEgeaEEMetzHEet alNeutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growthNat Med2010162192310.1038/nm.2084282180120081861Open DOISearch in Google Scholar
De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004; 10: 4895-900. doi: 10.1158/1078-0432.CCR-03-0760DeLarco JEWuertzBRFurchtLTThe potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8Clin Cancer Res200410489590010.1158/1078-0432.CCR-03-076015297389Open DOISearch in Google Scholar
Chen HC, Lin HC, Liu CY, Wang CH, Hwang T, Huang TT, et al. Neutrophil elastase induces IL-8 synthesis by lung epithelial cells via the mitogen-activated protein kinase pathway. J Biomed Sci 2004; 11: 49-58. doi: 10.1007/bf02256548ChenHCLinHCLiuCYWangCHHwangTHuangTTet alNeutrophil elastase induces IL-8 synthesis by lung epithelial cells via the mitogen-activated protein kinase pathwayJ Biomed Sci200411495810.1007/bf0225654814730209Open DOISearch in Google Scholar
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44. doi: 10.1038/nature07205MantovaniAAllavenaPSicaABalkwillFCancer-related inflammationNature20084544364410.1038/nature0720518650914Open DOISearch in Google Scholar
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immuneinflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 2017; 8: 75381-8. doi: 10.18632/oncotarget.18856ZhongJHHuangDHChenZYPrognostic role of systemic immuneinflammation index in solid tumors: a systematic review and meta-analysisOncotarget2017875381810.18632/oncotarget.18856565042829088873Open DOISearch in Google Scholar
Nicholas MN, Khoja L, Atenafu EG, Hogg D, Quirt I, Butler M, et al. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Melanoma Res 2018; 28: 571-7. doi: 10.1097/CMR.0000000000000468NicholasMNKhojaLAtenafuEGHoggDQuirtIButlerMet alPrognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experienceMelanoma Res201828571710.1097/CMR.000000000000046830067547Open DOISearch in Google Scholar
Zhan H, Ma JY, Jian QC. Prognostic significance of pretreatment neutrophilto-lymphocyte ratio in melanoma patients: A meta-analysis. Clin Chim Acta 2018; 484: 136-40. doi: 10.1016/j.cca.2018.05.055ZhanHMaJYJianQCPrognostic significance of pretreatment neutrophilto-lymphocyte ratio in melanoma patients: A meta-analysisClin Chim Acta20184841364010.1016/j.cca.2018.05.05529856976Open DOISearch in Google Scholar
Heppt MV, Heinzerling L, Kahler KC, Forschner A, Kirchberger MC, Loquai C, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer 2017; 82: 56-65. doi: 10.1016/j.ejca.2017.05.038HepptMVHeinzerlingLKahlerKCForschnerAKirchbergerMCLoquaiCet alPrognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionEur J Cancer201782566510.1016/j.ejca.2017.05.03828648699Open DOISearch in Google Scholar
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4: 250-5. doi: 10.1007/s11912-002-0023-1MahmoudFARiveraNIThe role of C-reactive protein as a prognostic indicator in advanced cancerCurr Oncol Rep20024250510.1007/s11912-002-0023-111937016Open DOISearch in Google Scholar
Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review. PLoS One 2015; 10: e0143080. doi: 10.1371/journal.pone.0143080ShrotriyaSWalshDBennani-BaitiNThomasSLortonCC-Reactive Protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic reviewPLoS One201510e014308010.1371/journal.pone.0143080470510626717416Open DOISearch in Google Scholar
Jiang Z, Li C, Zhao Z, Liu Z, Guan X, Yang M, et al. Abnormal liver function induced by space-occupying lesions is associated with unfavorable oncologic outcome in patients with colorectal cancer liver metastases. Biomed Res Int 2018; 2018: 9321270. doi: 10.1155/2018/9321270JiangZLiCZhaoZLiuZGuanXYangMet alAbnormal liver function induced by space-occupying lesions is associated with unfavorable oncologic outcome in patients with colorectal cancer liver metastasesBiomed Res Int20182018932127010.1155/2018/9321270597694029862297Open DOISearch in Google Scholar
